Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded at Truist Financial

Truist Financial upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. reduced their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. Wedbush reiterated a “neutral” rating and issued a $25.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. Leerink Partners reduced their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Guggenheim reduced their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Finally, Robert W. Baird decreased their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $60.47.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $19.38 on Wednesday. The stock has a market capitalization of $1.87 billion, a PE ratio of -3.32 and a beta of 0.16. The company’s 50-day moving average is $22.37 and its 200-day moving average is $28.09. Ultragenyx Pharmaceutical has a 1 year low of $18.29 and a 1 year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. During the same period in the previous year, the firm earned ($1.39) earnings per share. The business’s quarterly revenue was up 25.5% on a year-over-year basis. On average, analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the sale, the executive vice president directly owned 76,346 shares of the company’s stock, valued at $1,740,688.80. This represents a 9.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Howard Horn sold 1,635 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total value of $36,624.00. Following the completion of the transaction, the chief financial officer owned 85,034 shares in the company, valued at $1,904,761.60. This represents a 1.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 104,958 shares of company stock valued at $2,394,858. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently bought and sold shares of the company. Assetmark Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares during the last quarter. Huntington National Bank lifted its position in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical during the third quarter worth about $39,000. Smartleaf Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the last quarter. Finally, Covestor Ltd grew its position in Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Truist upgraded Ultragenyx to “strong-buy”, which could support the shares if follow‑through buying appears. Zacks/Truist upgrade
• Neutral Sentiment: Recent quarterly results were mixed: revenue beat estimates and grew year-over-year, but the company missed on EPS and remains unprofitable—results that leave room for differing analyst interpretations and volatility. (See recent company earnings release and estimates in coverage.)
• Negative Sentiment: Multiple securities‑litigation firms (Rosen, The Gross Law Firm, Faruqi & Faruqi, ClaimsFiler, Pomerantz and others) have issued shareholder alerts and reminders of an April 6, 2026 lead‑plaintiff deadline, signaling an active securities class action and increasing the risk of future legal costs and settlements. Rosen Law Firm notice ClaimsFiler notice Faruqi & Faruqi notice
• Negative Sentiment: Goldman Sachs downgraded Ultragenyx to Neutral and coverage noted the stock hit a new 12‑month low after the analyst move—an action that likely amplified selling pressure. Goldman Sachs downgrade 12‑month low report

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.